Condition deep-dive · 6 min read

Elevated homocysteine — what supplements actually lower it (and does lowering it matter?)

Updated 2026-05-21 · Reviewed by SupplementScore editors · No sponsorships

Homocysteine is a sulfur-containing amino acid produced during methionine metabolism. Plasma levels above ~12–15 μmol/L (mild-moderate) up to severe hyperhomocysteinemia (above 100 μmol/L, e.g., in untreated cystathionine β-synthase deficiency) are associated with cardiovascular events, cognitive decline, and pregnancy complications in large observational studies. The supplements that lower homocysteine are well-characterised: folate, B12, and B6. The harder question is whether lowering it improves cardiovascular outcomes — the major RCTs (HOPE-2, NORVIT, VISP) showed lowering but no consistent benefit on hard cardiovascular endpoints. The story for cognitive outcomes (VITACOG) and stroke (CSPPT) is more nuanced.

Read this first. Don't supplement folate to lower homocysteine before checking B12 status. High-dose folic acid in a B12-deficient adult can mask the haematological signs of B12 deficiency while neurological damage progresses unchecked — a documented harm pattern. The protocol is: test B12 first, then folate, then start.

What actually lowers homocysteine in trials

Tier 1 evidence · Largest contributor to lowering

Folate (5-MTHF or folic acid)

400–800 mcg/day of 5-MTHF or folic acid; higher doses (up to 5 mg) in specific clinical contexts

Folate has the largest single-vitamin effect on plasma homocysteine in trials — roughly 20–25% reduction in mildly elevated populations. 5-MTHF (the metabolically active form) is preferred in users with MTHFR variants (C677T, A1298C) that reduce conversion of folic acid. In US populations exposed to grain fortification, additional supplemental folate often makes only a small further difference; in unfortified populations the effect is larger.

Tier 1 evidence · Critical companion

Vitamin B12 (methylcobalamin or hydroxocobalamin)

500–1000 mcg/day oral; or sublingual; or IM in confirmed deficiency

B12 is necessary for the methionine synthase pathway. Older adults (reduced gastric acid, atrophic gastritis), strict vegans, and users on long-term proton-pump inhibitors or metformin are at higher B12-deficiency risk. Test serum B12 and (if borderline) methylmalonic acid before relying on serum B12 alone — serum B12 can be in the "low-normal" range with actual functional deficiency.

Tier 2 evidence · Smaller contributor

Vitamin B6 (P5P)

25–50 mg/day P5P (active form)

B6 supports the transsulfuration pathway by which homocysteine is converted to cystathionine. Effect on plasma homocysteine is smaller than folate or B12 in most populations, but B6 status affects the response after meals (post-methionine-load testing). Chronic high-dose B6 (above 100 mg/day for long periods) can cause sensory neuropathy — keep it at ≤50 mg/day P5P unless a clinician specifies otherwise.

Tier 2 evidence · Adjunct in trial regimens

Trimethylglycine (TMG / betaine)

3–6 g/day for severe elevation; 1.5–3 g/day for mild

Betaine provides an alternative methyl donor that converts homocysteine back to methionine via the BHMT pathway, parallel to the folate/B12 pathway. The clinical use is mostly in genetic hyperhomocysteinemias (e.g., CBS deficiency, severe MTHFR deficiency); modest signal in mild elevation. Trial doses for severe homocystinuria can be very high under specialist supervision.

Tier 3 evidence · Co-occurring deficiency

Riboflavin (B2)

100 mg/day; particularly relevant in MTHFR C677T homozygotes

Riboflavin is the cofactor for MTHFR enzyme function. Trials in C677T homozygotes (who have lower MTHFR enzyme activity) have shown lowering of blood pressure and modest homocysteine effects with B2 supplementation. The relevance for the broader population is smaller.

What the outcome trials show

Several large cardiovascular RCTs of B-vitamin homocysteine-lowering have been completed:

The pragmatic reading: in populations exposed to folate-fortified grain (the US and many other countries since the late 1990s) the cardiovascular benefit of additional B-vitamin lowering is small or null. In populations without fortification, or with documented B12 deficiency, or with elevated homocysteine plus cognitive concerns or MTHFR variants, the case for B-vitamin supplementation is stronger.

What to skip

What to track

Plasma total homocysteine, fasting, at baseline and at 8–12 weeks of supplementation. Pair with serum B12, MMA (if B12 borderline), serum folate, and a CBC. Optional: MTHFR genotyping if there's a personal or family history of premature CVD/thrombosis (the genotype changes the choice of folate form rather than whether to treat). Annual recheck once stable.

Practical quick-start. Test homocysteine, B12, MMA (if B12 low-normal), folate, and ferritin. If homocysteine is mildly elevated (12–20 μmol/L) and B12 is replete: 5-MTHF 400–800 mcg/day plus methyl B12 500 mcg/day; add P5P 25 mg/day. Recheck at 12 weeks; expect 20–25% reduction. If homocysteine is markedly elevated (above 30 μmol/L) or pregnancy planning is involved, this is endocrinology / genetics territory.

Educational reference, not medical advice. Coordinate B-vitamin supplementation with primary care, particularly in users on methotrexate (folate has specific considerations), levodopa (B6 interactions), and in pregnancy.

Sources

Read more: